Nanobiotix Stock: Increase of 6.92% at Monday's Opening
The French biotech is among the top gainers on the Paris stock exchange at the start of the session, driven by a spectacular momentum that has been building for several weeks.
Significant Opening Surge
The biotechnology value rose by 6.92% at the opening, bringing the price to €23.95, up from €22.40 at the close on Friday. This increase is part of a remarkable upward trend: the stock has jumped 40.88% over the past seven days, 438.2% over three months, and 441.6% over one year. For comparison, the CAC 40 has shown an annual performance of 5.02% and is up 0.51% this Monday morning. The traded volumes remain moderate at 0.55% of the capital, a level that reflects some restraint despite the magnitude of recent movements.
Following Positive Announcements
This surge follows several positive announcements. On October 1, Nanobiotix presented encouraging data from a Phase 1 study evaluating its product JNJ-1900 (NBTXR3) in patients with locally advanced esophageal cancer. The treatment was well tolerated, with an objective response rate of 69%, including 6 complete responses out of 13 treated patients. A few days later, on October 6, analysts at Jefferies raised their price target to €21, confirming their buy recommendation. The stock had already been among the top gainers on the SRD on October 8, with a gain of 21.84% to €22.20.
Technical Resistance Overcome
From a technical standpoint, the stock has just touched its technical resistance at €23.90, a level that the current price slightly exceeds, while it is very close to the upper boundary of the Bollinger Bands, positioned at €23.97. This configuration indicates a maximum extension of the short-term bullish movement. The Relative Strength Index (RSI), which measures the speed and magnitude of price changes, reaches 86, signaling a pronounced overbought zone. The Chaikin Money Flow, incorporating volume to measure buying or selling pressure, shows a value of 0.28, indicating dominant buying flows in the recent period. The MACD, a momentum indicator, is at 3.45, significantly above its signal line at 2.56, confirming the persistence of the bullish momentum. The monthly volatility, measured at 36.17%, illustrates the extent of recent price movements. Finally, with a beta of 0.16, Nanobiotix shows very low sensitivity to fluctuations in the CAC 40, which may interest investors looking for exposure that is minimally correlated to the market.
